Danaher Corporation, a major player in life sciences and diagnostics, has acquired Genedata AG, a Swiss software company known for its contributions to biopharmaceutical research and development.
Founded in 1997 and based in Basel, Switzerland, Genedata has established itself as a key provider of software that turns complex scientific data into useful insights. The company’s tools are widely used by biopharmaceutical companies and biotech firms to improve the efficiency and productivity of their research and development efforts.
This acquisition is expected to broaden Danaher’s capabilities in drug discovery and development, helping speed up the creation of new therapies. Genedata and Danaher have a history of working together, which has led to this next step in their relationship.
Dr. Othmar Pfannes, Founder and President of Genedata, emphasized the importance of his team in the company’s success. “Our team’s dedication and expertise have been crucial in building the trust of our customers,” he said. “As part of Danaher, we’ll continue to focus on solving the complex challenges faced by our clients.”
Greg Milosevich, Vice President of Danaher’s DH Life Sciences LLC subsidiary, shared his thoughts on the acquisition. “We’ve always respected Genedata’s innovative approach and deep scientific understanding,” he said. “We’re excited to bring their team into the Danaher family and to continue working together to support the development of new therapies.”
This acquisition reflects Danaher’s ongoing effort to enhance biopharmaceutical research through collaboration and innovation.